We would like to thank Dr Kim for showing interest in our article. As the author pointed out, we did not include the cases with retinal angiomatous proliferation (RAP) in our study owing to its rarity. Our study was conducted as a multicenter study with 3 university hospitals, and at each institute the eyes with RAP were treated by its own established protocol; 2 institutes applied the combined therapy of photodynamic therapy with verteporfin followed by intravitreal aflibercept injection, whereas 1 institute used aflibercept monotherapy. As a result, only 1 eye of a 76-year-old woman with RAP was treated with 3 monthly intravitreal aflibercept injections during the study period. Accordingly, we have decided not to include the patients with RAP in our study. Just as a reference, in the only 1 eye with RAP that was ultimately excluded, subfoveal choroidal thickness decreased from 158 μm to 151 μm at 1 month, 139 μm at 2 months, and 130 μm at 3 months, after 3 monthly intravitreal aflibercept injections. The percentage change in subfoveal choroidal thickness during 3 months was 82.3%. Although the decrease in choroidal thickness may not necessarily reflect the decrease in choroidal blood flow, we should keep in mind the possibility of detrimental effect on the already thin choroid seen in eyes with RAP. It is not possible to draw a definite conclusion at this time, and further studies with a large number of cases are warranted.